Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1803-1810

  Salek, Cyril ^a,b   Minarikova, Petra ^b   Benesova, Lucie ^a   Nosek, Vladimir ^b   Strnad, Robin ^c   Zavoral, Miroslav ^b   Minarik, Marek ^a  

^a Laboratory for Molecular Genetics and Oncology   (Czech Republic)

^b CENTRAL MILITARY HOSPITAL   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

DPC4; K ras; p16; p53; Pancreatic cancer; Prognostic markers

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; K RAS PROTEIN; PROTEIN P53; SMAD4 PROTEIN;

ADULT; ALLELE; ARTICLE; ASPIRATION BIOPSY; CANCER STAGING; CANCER SURVIVAL; CAPILLARY ELECTROPHORESIS; CHROMOSOME 18Q; CHROMOSOME 9P; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; FEMALE; GENE MUTATION; GIEMSA STAIN; HETEROZYGOSITY LOSS; HUMAN; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS;

ALLELES; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 9; GENES, P53; GENES, RAS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 67650081077     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA and Clegg L: SEER Cancer Statistics Review, 1973-1998. National Cancer Institute: Bethesda, 2001.
2. Gudjonsson B: Survival statistics gone awry. Pancreatic cancer, A case in point. J Clin Gastroenterol 35: 180-184, 2002. (Pubitemid 34815858)
3. Hruban RH, Goggins M, Parsons J and Kern SE: Progression model for pancreatic cancer, Clin Cancer Res 6: 2969-2972, 2000.
4. Biankin AV, Kench JG, Dijkman FP, Biankin SA and Henshall SM: Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 35(1): 14-24, 2003. (Pubitemid 36349941)
5. Deramaudt T and Rustgi AK: Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 1756(2): 97-101, 2005. (Pubitemid 41773136)
6. Hermanova M, Lukas Z, Nenutil R, Brazdil J, Kroupova I, Kren L, Pazourkova M, Ruzicka M and Dite P: Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pacreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1). Neoplasma 51: 77-83, 2004. (Pubitemid 38596137)
7. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte I, Schmiegel W, Baylin SB, Kern SE and Herman JG: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126-3130, 1997. (Pubitemid 27351723)
8. Hua Z, Zhang YC, Hu XM and Jia ZG: Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol 9(12): 2764-2767, 2003. (Pubitemid 38054456)
9. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092): 424-430, 2006.
10. Pietsch EC, Sykes SM, McMahon SB and Murphy ME: The p53 family and programmed cell death. Oncogene 27(50): 6507-6521, 2008.
11. Sherr, CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2: 731-737, 2001.
12. Massague J and Wotton D: Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19: 1745-1754, 2000. (Pubitemid 30204386)
13. Schwarte-Waldhoff I and Schmiegel W: Smad4 transcriptional pathways and angiogenesis. Int J Gastrointest Cancer 31(1-3): 47-59, 2002.
14. Jimeno A and Hidalgo M Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 5(4): 787-796, 2006. (Pubitemid 43724577)
15. Salek C, Benesova L, Zavoral M, Nosek V, Kasperova L, Ryska M, Strnad R, Traboulsi E and Minarik M: Evaluation of K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 13(27): 3714-3720, 2007. (Pubitemid 47202169)
16. AJCC Cancer Staging Handbook. 6th Edition. New York: Springer Verlag, 2002.
17. Minarik M, Minarikova L, Bjorheim J and Ekstrom PO: Cycling gradient capillary electrophoresis: a low-cost tool for high-throughput analysis of genetic variations. Electrophoresis 24: 1716-1722, 2003. (Pubitemid 38088958)
18. Trkova M, Babjuk M, Duskova J, Benesova-Minarikova L, Soukup V, Mares J, Minarik M and Sedlacek Z: Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. Cancer Lett 242: 68-76, 2006. (Pubitemid 44508645)
19. Lassus H, Salovaara R, Aaltonen LA, and Butzow R: Alelic Analysis of Serous Ovarian Carcinoma Reveals Two Putative Tumor Suppressor Loci at 18q22-q23 Distal to SMAD4, SMAD2, and DCC. Amer J Pathol 159(1): 35-42, 2001. (Pubitemid 33704189)
20. Kawesha A, Ghaneh P, Andrén-Sandberg A, Ograed D, Skar R, Dawiskiba S., Evans JD, Campbell F, Lemoine N and Neoptolemos JP: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4a), p21 (WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89(6): 469-474, 2000.
21. Takahashi K, Yamao K, Okubo K, Sawaki A, Mizuno N, Ashida R, Koshikawa T, Ueyama Y, Kasugai K, Hase S and Kakumu S: Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 61: 76-79, 2005. (Pubitemid 40169815)
22. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Strzelczyk J, Janiak A and Malecka-Panas E: Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Hepatogastroenterology 53(70): 608-612, 2006. (Pubitemid 44386969)
23. Jeong J, Park YN, Park JS, Yoon DS, Chi HS and Kim BR: Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J 46(4): 516-525, 2005. (Pubitemid 41283063)
24. Dong M, Nio Y, Yamasawa K, Toga T, Yue L and Harada T: p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 82(2): 111-120, 2003. (Pubitemid 36164446)
25. Ghaneh P, Kawesha A, Evans JD and Neoptolemos JP: Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 9(1): 1-11, 2002. (Pubitemid 34477366)
26. Yokoyama M, Yamanaka Y, Friess H, Buchler M and Korc M: p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 14: 2477-2483, 1994.
27. Sato N and Goggins M: Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. J Hepatolibilary Pancreat Surg 13: 280-285, 2006. (Pubitemid 44111335)
28. Sato N and Goggins M: The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 13: 286-295, 2006. (Pubitemid 44111336)
29. Ohtsubo K, Watanabe H, Yamaguchi Y, Hu YX, Motoo Y, Okai T and Sawabu N: Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol 38: 663-671, 2003. (Pubitemid 36974980)
30. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH and Goggins M: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7(12): 3853-3856, 2001. (Pubitemid 34044636)
31. Yatsuoka T, Sunamura M, Furukawa T, Fukushige S, Yokoyama T, Inoue H, Shibuya K, Takeda K, Matsuno S and Horii A: Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6p/17p and 12q/18q in human pancreatic ductal adenocarcinoma. Am J Gastroenterol 95(8): 2080-2085, 2000. (Pubitemid 30629310)
32. Weinstein M, Yang X and Deng CX: Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev 11: 49-58, 2000. (Pubitemid 30169725)
33. Fang L: SMAD4/DPC4 and pancreatic cancer survival. Clin Cancer Res 7(12): 3853-3856, 2001.
34. Fry LC, Monkemuller K and Malfertheiner P: Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 393(6): 883-890, 2008.
35. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS and Somerfield MR, Hayes DF and Bast RC: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33): 5313-5327, 2006.
36. Goggins M: Molecular markers of early pancreatic cancer. J Clin Oncol 23: 4523-4531, 2005.
37. Jiang XT, Tao HQ and Zou SC: Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3: 464-468, 2004. (Pubitemid 39173087)
38. DiMagno EP, Reber HA and Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma: American Gastroenterological Asociation. Gastroenterology 117: 1464-1484, 1999.
39. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C and Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24(18): 2897-2902, 2006. (Pubitemid 46630592)
40. Boeck S, Schulz C, Stieber P, Holdenrieder S, Weckbach S and Heinemann V: Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie 30: 39-42, 2007.
41. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z and Pour PM: Relationship of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70: 255-264, 1987.
42. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM and Goldenberg DM: New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 24(2): 252-258, 2006. (Pubitemid 46622054)
43. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Büchler MW, Aubert JP and Batra SK: Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 7(12): 4033-4040, 2001. (Pubitemid 34044624)